{
    "title": "108_hr5278",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``Community Pharmacy Preservation Act \nof 2004''.\n\nSEC. 2. APPLICATION OF THE ANTITRUST LAWS TO INDEPENDENT PHARMACIES \n              NEGOTIATING WITH HEALTH PLANS.\n\n    (a) In General.--Any independent pharmacies who are engaged in \nnegotiations with a health plan regarding the terms of any contract \nunder which the pharmacies provide health care items or services for \nwhich benefits are provided under such plan shall, in connection with \nsuch negotiations, be entitled to the same treatment under the \nantitrust laws as the treatment to which bargaining units which are \nrecognized under the National Labor Relations Act are entitled in \nconnection with such collective bargaining. Such a pharmacy shall, only \nin connection with such negotiations, be treated as an employee engaged \nin concerted activities and shall not be regarded as having the status \nof an employer, independent contractor, managerial employee, or \nsupervisor.\n    (b) Protection for Good Faith Actions.--Actions taken in good faith \nreliance on subsection (a) shall not be the subject under the antitrust \nlaws of criminal sanctions nor of any civil damages, fees, or penalties \nbeyond actual damages incurred.\n    (c) Limitation.--\n            (1) No new right for collective cessation of service.--The \n        exemption provided in subsection (a) shall not confer any new \n        right to participate in any collective cessation of service to \n        patients not already permitted by existing law.\n            (2) No change in national labor relations act.--This \n        section applies only to independent pharmacies excluded from \n        the National Labor Relations Act. Nothing in this section shall \n        be construed as changing or amending any provision of the \n        National Labor Relations Act, or as affecting the status of any \n        group of persons under that Act.\n    (d) Effective Date.--The exemption provided in subsection (a) shall \napply to conduct occurring beginning on the date of the enactment of \nthis Act.\n    (e) Limitation on Exemption.--Nothing in this section shall exempt \nfrom the application of the antitrust laws any agreement or otherwise \nunlawful conspiracy that excludes, limits the participation or \nreimbursement of, or otherwise limits the scope of services to be \nprovided by any independent pharmacy or group of independent pharmacies \nwith respect to the performance of services that are within their scope \nof practice as defined or permitted by relevant law or regulation.\n    (f) No Effect on Title VI of Civil Rights Act of 1964.--Nothing in \nthis section shall be construed to affect the application of title VI \nof the Civil Rights Act of 1964.\n    (g) No Application to Federal Programs.--Nothing in this section \nshall apply to negotiations between independent pharmacies and health \nplans pertaining to benefits provided under any of the following:\n            (1) The Medicaid Program under title XIX of the Social \n        Security Act (42 U.S.C. 1396 et seq.).\n            (2) The SCHIP program under title XXI of the Social \n        Security Act (42 U.S.C. 1397aa et seq.).\n            (3) Chapter 55 of title 10, United States Code (relating to \n        medical and dental care for members of the uniformed services).\n            (4) Chapter 17 of title 38, United States Code (relating to \n        Veterans' medical care).\n            (5) Chapter 89 of title 5, United States Code (relating to \n        the Federal employees' health benefits program).\n            (6) The Indian Health Care Improvement Act (25 U.S.C. 1601 \n        et seq.).\n    (h) Definitions.--For purposes of this section:\n            (1) Antitrust laws.--The term ``antitrust laws''--\n                    (A) has the meaning given it in subsection (a) of \n                the first section of the Clayton Act (15 U.S.C. 12(a)), \n                except that such term includes section 5 of the Federal \n                Trade Commission Act (15 U.S.C. 45) to the extent such \n                section 5 applies to unfair methods of competition; and\n                    (B) includes any State law similar to the laws \n                referred to in subparagraph (A).\n            (2) Health plan and related terms.--\n                    (A) In general.--The term ``health plan'' means a \n                group health plan or a health insurance issuer that is \n                offering health insurance coverage.\n                    (B) Health insurance coverage; health insurance \n                issuer.--The terms ``health insurance coverage'' and \n                ``health insurance issuer'' have the meanings given \n                such terms under paragraphs (1) and (2), respectively, \n                of section 733(b) of the Employee Retirement Income \n                Security Act of 1974 (29 U.S.C. 1191b(b)).\n                    (C) Group health plan.--The term ``group health \n                plan'' has the meaning given that term in section \n                733(a)(1) of the Employee Retirement Income Security \n                Act of 1974 (29 U.S.C. 1191b(a)(1)).\n            (3) Independent pharmacy.--The term ``independent \n        pharmacy'' means a pharmacy which is not owned (or operated) by \n        a publicly traded company. For purposes of the previous \n        sentence, the term ``publicly traded company'' means a company \n        that is an issuer within the meaning of section 2(a)(7) of the \n        Sarbanes-Oxley Act of 2002 (15 U.S.C. 7201(a)(7)).\n\nSEC. 3. REQUIREMENTS RELATING TO PHARMACY BENEFIT MANAGERS.\n\n    (a) Prohibition on Cross Ownership.--\n            (1) In general.--No pharmaceutical drug manufacturer may \n        have a controlling interest in an entity that is a pharmacy \n        benefit manager.\n            (2) Penalty.--The Secretary of Health and Human Services \n        may issue such civil penalties for a violation of paragraph (1) \n        as the Secretary of Health and Human Services determines \n        necessary.\n    (b) Drug Interchange.--\n            (1) Prohibitions.--\n                    (A) Cost increase.--A pharmacy benefit manager \n                shall not make any drug interchange proposal for an \n                individual who is served by such manager where the net \n                cost of the drug to which the prescription would be \n                changed exceeds that of the drug from which the \n                prescription would be changed.\n                    (B) Disclosure to individual.--A pharmacy benefit \n                manager shall not make any drug interchange for an \n                individual who is served by such manager unless the \n                pharmacy benefit manager discloses to the individual, \n                in a clear and conspicuous manner, the savings to the \n                individual associated with such interchange.\n                    (C) Generics.--A pharmacy benefit manager shall not \n                make any drug interchange proposal for an individual \n                who is served by such manager if the drug from which \n                the prescription would be changed has generic \n                equivalents and the drug to which the prescription \n                would be changed has no generic equivalents, unless the \n                drug to which the prescription would be changed has a \n                lower net cost to the individual than does each of the \n                generic equivalents of the drug from which the \n                prescription would be changed.\n            (2) Penalty.--A pharmacy benefit manager that violates \n        subparagraph (A), (B), or (C) of paragraph (1) with respect to \n        an individual and presents a claim for payment to the United \n        States Government as reimbursement for services to such \n        individual, shall be considered in violation of section 3729 of \n        title 31, United States Code.\n    (c) Disclosure of Compensation From Drug Manufacturers.--\n            (1) Quarterly and annual disclosures.--At the end of each \n        fiscal year quarter, each pharmacy benefit manager shall \n        disclose--\n                    (A) to the client plans of such manager and to the \n                Antitrust Division of the Department of Justice, all \n                compensation and remuneration that the pharmacy benefit \n                manager received during such fiscal year quarter from a \n                pharmaceutical drug manufacturer, including, regardless \n                of how categorized, market share incentives, \n                commissions, mail service purchase discounts, and \n                administrative or management fees; and\n                    (B) to the client plans of such manager, any fees \n                received for sales of utilization data to a \n                pharmaceutical drug manufacturer.\n            (2) Disclosure at contracting stage.--Each pharmacy benefit \n        manager shall disclose to each client plan and prospective \n        client plan of such manager, in advance of executing an \n        agreement with such plan, information relating to the pharmacy \n        benefit manager's methodology of soliciting and receiving \n        payments from pharmaceutical drug manufacturers.\n    (d) Definitions.--For purposes of this section:\n            (1) Client plan.--The term ``client plan'' means a \n        pharmaceutical plan in which the entity that offers such plan \n        to its beneficiaries contracts directly with a pharmacy benefit \n        manager to provide or administer such plan.\n            (2) Drug interchange.--The term ``drug interchange'' means \n        any change from one prescription drug to another prescription \n        drug that is intended to address or treat the same illness or \n        condition.\n\nSEC. 4. COMMUNITY PHARMACY ACCESS STANDARDS UNDER THE MEDICARE \n              OUTPATIENT PRESCRIPTION DRUG PROGRAM.\n\n    In establishing rules under subparagraph (C) of section 1860D-\n4(b)(1) of the Social Security Act, as added by the Medicare \nPrescription Drug, Improvement, and Modernization Act of 2003 (Public \nLaw 108-173), for convenient access to non-mail-order pharmacies \nconsistent with the application of standards under clause (ii) of such \nsubparagraph, the Secretary of Health and Human Services shall provide \nfor application of the following standards:\n            (1)(A) In each urban area, at least 90 percent of Medicare \n        beneficiaries in a plan's service area, on average, live within \n        2 miles of a retail pharmacy participation in the prescription \n        drug plan's or MA-PD plan's network.\n            (B) In each suburban area, at least 90 percent of Medicare \n        beneficiaries in a plan's service area, on average, live within \n        5 miles of a retail pharmacy participation in the prescription \n        drug plan's or MA-PD plan's network.\n            (C) In each rural area, at least 70 percent of Medicare \n        beneficiaries in a plan's service area, on average, live within \n        15 miles of a retail pharmacy participation in the prescription \n        drug plan's or MA-PD plan's network.\n            (D) There shall be no averaging of such distances across or \n        among urban, suburban, and rural areas.\n            (2) The rules shall require plans to measure traveling \n        distances from beneficiaries' homes to community pharmacies \n        based on commonly traveled routes."
}